Contact

North Current Home About Services Legal Status Safety & Risks Access Options Contact Independent information resource Ibogaine Canada A cautious, plainspoken guide to ibogaine’s evolving place in Canada: regulation, research, safety, and the public-health context around an experimental intervention. HIGH STAKES. Ibogaine is publicly discussed far more than it is clinically available in Canada. The essential frame Not a broad-access market. Ibogaine is a psychoactive alkaloid derived from the African shrub Tabernanthe iboga . In Canada, the subject spans legal status, clinical research, addiction treatment seeking, safety concerns, commercial activity, and public-health responses to unauthorized use. The basic pharmacology of ibogaine helps explain why it is discussed as a powerful intervention rather than a routine medication. In practical terms, ibogaine is not mainstream Canadian medicine. It is an experimental, addiction-focused intervention with a narrow regulatory pathway and a much wider public profile. Health Canada’s prescription drug list notice on multiple additions is part of the official context that shapes how the substance is treated. Why it matters now 23% Overdose deaths declined National overdose deaths in Canada declined by 23% in 2025 compared with 2024, but the scale of substance-related harm remains significant enough to sustain demand for novel interventions. 10K+ People seeking treatment One estimate cited in recent literature places the number of people who had sought ibogaine treatment for substance use disorder above 10,000 by 2023. 2026 A proof-or-retreat year Credible regulated research could advance, or the topic could remain shaped by niche clinics, activism, uneven access, and reports of harm. Public attention / clinical limits Demand is real. So are the constraints. Media narratives about addiction, trauma, veterans, and psychedelics have brought ibogaine into wider view. The CBC’s interactive account, Ibogaine: The Last Trip , il

Contact

A note on reaching us